Can GLP-1 Medications Help Asthma Too? What New Research Presented This Year Actually Shows

Key Takeaways

• Research presented at the 2026 AAAAI Annual Meeting found that GLP-1 receptor agonists (semaglutide, tirzepatide, and liraglutide) were associated with a 12 to 15 percent reduction in asthma exacerbations over three years in adults with overweight or obesity who do not have diabetes.
• The effect held consistently across overweight, obese, and morbidly obese groups, and it appeared even in patients without diabetes, which argues against the benefit simply being about blood sugar control.
• Researchers believe the benefit likely comes from a combination of weight loss easing the mechanical burden on the lungs and a possible direct anti-inflammatory effect of GLP-1 signaling on the airways.
• This is real-world, retrospective data, not a randomized controlled trial, and the effect size is modest compared with dedicated asthma biologics like dupilumab or omalizumab, which can reduce exacerbations by half or more.

Why this is generating so much attention

GLP-1 medications have become some of the most talked about drugs in medicine over the past few years, largely for diabetes and weight management. What is newer is research suggesting they may have effects that reach well beyond metabolism, and asthma is one of the conditions now being studied. At the 2026 AAAAI Annual Meeting in Philadelphia, researchers presented data suggesting a meaningful link between GLP-1 use and fewer asthma flare-ups in people with excess weight, and the finding is exactly the kind of crossover result that tends to generate interest well beyond the specialty that produced it.

What the research actually found

The study design

Researchers used data from the TriNetX global health research network to compare asthma exacerbation rates over a three year period between non-diabetic adults with excess weight who started a GLP-1 medication and those who did not. The study included more than 3,000 patients across overweight, obese, and morbidly obese categories, using propensity matching to make the comparison groups as similar as possible.

The results

Across all three weight categories, GLP-1 initiation was associated with a statistically significant reduction in asthma exacerbations, ranging from about 12 to 15 percent depending on the group. In practical terms, researchers described this as roughly one fewer asthma flare for every seven to eight patients treated over the three year period. A related study in adolescents with obesity found an even larger relative reduction, along with fewer emergency department visits and less need for oral steroids.

This is an interesting and genuinely useful data point, but it is important to be precise about what it does and does not show. This was not a trial designed specifically to test GLP-1s as an asthma treatment, and the effect size is meaningfully smaller than what we see with biologics built specifically for type 2 airway inflammation. What it does suggest is that if a patient with asthma and excess weight is already a candidate for a GLP-1 medication for weight or metabolic reasons, better asthma control may be a reasonable additional benefit to expect.

— Yuliya Leviyev, NP, Allergy Asthma

What this means if you have asthma and are on or considering a GLP-1

If you already take a GLP-1 medication for diabetes or weight management and also have asthma, this research offers a plausible explanation if you have noticed your asthma feeling better controlled since starting. If you are considering a GLP-1 for weight or metabolic reasons and separately manage asthma, this is worth mentioning to both your prescribing physician and your allergist, since it may factor into the overall conversation about benefits.

What this is not is a reason to start a GLP-1 medication specifically to treat asthma, or a substitute for controller therapy, inhaled steroids, or biologics already prescribed for moderate to severe asthma. The data available so far comes from retrospective, real-world analysis rather than a trial designed to test this specific question, so it should inform the conversation rather than change an existing asthma treatment plan on its own.

When to bring this up at a visit

This is a good topic to raise if you have asthma along with overweight or obesity and are already discussing GLP-1 options with your primary care physician, if your asthma control has changed since starting one of these medications and you want to understand why, or if you simply want a clearer picture of how weight, metabolism, and airway inflammation connect in your specific case.

Disclaimer: This content is educational and does not substitute for medical advice. Always consult your physician for personal medical questions.